Lorenzo Marconi1, Thomas Stonier2, Rafael Tourinho-Barbosa3, Caroline Moore4, Hashim U Ahmed5, Xavier Cathelineau3, Mark Emberton6, Rafael Sanchez-Salas3, Paul Cathcart7. 1. Urology Centre, Guy's and St. Thomas NHS Foundation Trust, London, UK. Electronic address: lorenzooliveiramarconi@gmail.com. 2. Department of Urology, Kings College Hospital, London, UK. 3. Department of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France. 4. Department of Urology, University College London Hospitals, London, UK. 5. Imperial College Healthcare NHS Trust, London, UK; Imperial College London, London, UK. 6. Department of Urology, University College London Hospitals, London, UK; Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK. 7. Urology Centre, Guy's and St. Thomas NHS Foundation Trust, London, UK. Electronic address: pjcathcart@hotmail.com.
Abstract
There are few data on the outcomes and toxicity of radical prostatectomy (RP) among men experiencing local recurrence of prostate cancer (PC) following focal therapy (FT). To characterise perioperative, oncological, and functional outcomes after salvage robot-assisted RP (S-RALP) and determine the risk factors for S-RALP failure, we conducted a multicentre cohort study of 82 patients undergoing S-RALP after FT. All had histological confirmation of PC recurrence, with metastatic disease excluded using pelvic magnetic resonance imaging, a bone scan, and/or positron emission tomography/computed tomography. Progression-free survival was 74%, 48%, and 36% at 12, 24, and 36mo after surgery, respectively. The 12-mo continence rate was 83%. There were no intraoperative complications and no major postoperative complications. On multivariable analysis, only infield recurrence (hazard ratio [HR] 3.77, 95% confidence interval [CI] 1.11-12.85; p=0.03) and pT3b stage (HR 5.0, 95% CI 1.53-16.39; p=0.008) were independent predictors of recurrence. This study represents the largest series of salvage surgery after FT and shows that this approach is safe with no increase in toxicity when compared to primary RALP. Men identified as having infield recurrence after FT appear to have phenotypically aggressive disease and should be counselled regarding the potential need for a multimodal therapeutic approach. PATIENT SUMMARY: Robotic surgery after focal therapy for prostate cancer is safe and achieves postoperative continence results similar to those for robotic radical prostatectomy in treatment-naïve patients. However, if the cancer recurrence is within the previously treated field, the oncological prognosis seems to be worse.
There are few data on the outcomes and toxicity of radical prostatectomy (RP) among men experiencing local recurrence of prostate cancer (PC) following focal therapy (FT). To characterise perioperative, oncological, and functional outcomes after salvage robot-assisted RP (S-RALP) and determine the risk factors for S-RALP failure, we conducted a multicentre cohort study of 82 patients undergoing S-RALP after FT. All had histological confirmation of PC recurrence, with metastatic disease excluded using pelvic magnetic resonance imaging, a bone scan, and/or positron emission tomography/computed tomography. Progression-free survival was 74%, 48%, and 36% at 12, 24, and 36mo after surgery, respectively. The 12-mo continence rate was 83%. There were no intraoperative complications and no major postoperative complications. On multivariable analysis, only infield recurrence (hazard ratio [HR] 3.77, 95% confidence interval [CI] 1.11-12.85; p=0.03) and pT3b stage (HR 5.0, 95% CI 1.53-16.39; p=0.008) were independent predictors of recurrence. This study represents the largest series of salvage surgery after FT and shows that this approach is safe with no increase in toxicity when compared to primary RALP. Men identified as having infield recurrence after FT appear to have phenotypically aggressive disease and should be counselled regarding the potential need for a multimodal therapeutic approach. PATIENT SUMMARY: Robotic surgery after focal therapy for prostate cancer is safe and achieves postoperative continence results similar to those for robotic radical prostatectomy in treatment-naïve patients. However, if the cancer recurrence is within the previously treated field, the oncological prognosis seems to be worse.
Authors: Alex Z Wang; Amir H Lebastchi; Luke P O'Connor; Michael Ahdoot; Sherif Mehralivand; Nitin Yerram; Samir S Taneja; Arvin K George; Rafael Sanchez-Salas; John F Ward; Pilar Laguna; Jean de la Rosette; Peter A Pinto Journal: World J Urol Date: 2021-01-02 Impact factor: 4.226
Authors: James E Thompson; Ashwin N Sridhar; Greg Shaw; Prabhakar Rajan; Anna Mohammed; Timothy P Briggs; Senthil Nathan; John D Kelly; Prasanna Sooriakumaran Journal: BMC Urol Date: 2020-07-01 Impact factor: 2.264
Authors: Łukasz Nyk; Wojciech Michalak; Stanisław Szempliński; Rafał Woźniak; Bartłomiej Zagożdżon; Wojciech Krajewski; Piotr Kryst; Hubert Kamecki; Sławomir Poletajew Journal: J Pers Med Date: 2022-02-09
Authors: Jost von Hardenberg; Hannes Cash; Daniel Koch; Angelika Borkowetz; Johannes Bruendl; Sami-Ramzi Leyh-Bannurah; Timur H Kuru; Karl-Friedrich Kowalewski; Daniel Schindele; Katharina S Mala; Niklas Westhoff; Andreas Blana; Martin Schostak Journal: World J Urol Date: 2021-04-21 Impact factor: 4.226